GenSpera, Inc. (GNSZ) Releases Updated Corporate Video: "GenSpera has targeted its active ingredient thapsigargin to kill only the cells we select: cancer"

SAN ANTONIO, June 23, 2014 /PRNewswire/ -- GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, releases the updated corporate video explaining its lead drug candidate, G-202.  

The video explains, "The thapsigargin plant, a weed that grows abundantly in the Mediterranean, kills by disruption of the calcium balance in cells, all cells. Now, Genspera has targeted its active ingredient thapsigargin, to kill only the cells we select: cancer."

Chairman and CEO, Craig Dionne, PhD. says, "We have taken the powerful toxin thapsigargin and found a way to keep it inactive until it finds the cells it has been programmed to seek. Then it releases its active ingredient and destroys all of the targeted cells." 

In the case of GenSpera's first drug, G-202, this target is PSMA, an enzyme which is only found on the walls of the blood vessels that feed cancer tumors, regardless of the type of cancer.

See the Video:
http://youtu.be/jULjEul-mBk 

Chairman and CEO, Craig Dionne, PhD., will be presenting at the 2014 BIO International Convention on Tuesday, June 24^th at 11:15 PDT in San Diego, CA, where he will be providing an update on G-202. The Company's BIO presentation will be available on June 24^th to investors.

About GenSpera
GenSpera's technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system that provides for the targeted release of drug candidates within a tumor. Unlike typical chemotherapeutic agents, thapsigargin results in cell death irrespective of the rate of cell division, which may provide an effective approach to kill both fast- and slow-growing cancers. GenSpera's lead drug candidate, G-202, is activated by the enzyme PSMA, which is found at high levels in the vasculature of liver and glioblastoma cancers and in the vasculature of almost all other solid tumors. G-202 is therefore expected to have potential efficacy in a wide variety of tumor types.

G-202 Phase II clinical trials are underway in both hepatocellular carcinoma and glioblastoma patients.

For more information, please visit the company's website: www.genspera.com or follow us on Twitter @GenSperaNews.

Cautionary Statement Regarding Forward Looking Information
This news release may contain forward-looking statements. Investors are cautioned that statements in this press release regarding potential applications of GenSpera's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties will be detailed from time to time in GenSpera's periodic reports filed with the Securities and Exchange Commission.

Contact

Company:
Craig Dionne, PhD, CEO
GenSpera, Inc.
+1-210-479-8112                                     

Investors:
John Baldissera
BPC Financial Marketing
800-368-1217

Media: 800-665-0411

SOURCE GenSpera, Inc.